Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $56.00

Shares of Tempus AI, Inc. (NASDAQ:TEMGet Free Report) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $56.00.

A number of equities research analysts have recently weighed in on TEM shares. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Loop Capital raised their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company.

Get Our Latest Analysis on TEM

Insider Activity

In other news, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 845,041 shares of company stock valued at $35,125,473.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently added to or reduced their stakes in TEM. NEA Management Company LLC acquired a new position in shares of Tempus AI in the 2nd quarter valued at $160,048,000. Novo Holdings A S acquired a new position in Tempus AI in the second quarter worth about $142,605,000. Revolution Growth Management Company Inc. bought a new position in Tempus AI during the second quarter worth about $128,133,000. ARK Investment Management LLC boosted its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after purchasing an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. acquired a new stake in Tempus AI during the second quarter valued at approximately $54,289,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Up 11.7 %

Shares of NASDAQ:TEM opened at $38.25 on Tuesday. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a fifty day simple moving average of $48.93 and a 200 day simple moving average of $46.74.

Tempus AI Company Profile

(Get Free Report

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Further Reading

Analyst Recommendations for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.